Advanced glycation end products and the kidney

被引:301
作者
Bohlender, JM [1 ]
Franke, S [1 ]
Stein, G [1 ]
Wolf, G [1 ]
机构
[1] Univ Klin Jena, Innere Med Klin 3, Dept Internal Med 3, Jena, Germany
关键词
RAGE; diabetic nephropathy; progression of renal disease; inflammation; glycoxidation;
D O I
10.1152/ajprenal.00398.2004
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Advanced glycation end products (AGEs) are a heterogeneous group of protein and lipids to which sugar residues are covalently bound. AGE formation is increased in situations with hyperglycemia ( e. g., diabetes mellitus) and is also stimulated by oxidative stress, for example in uremia. It appears that activation of the renin-angiotensin system may contribute to AGE formation through various mechanisms. Although AGEs could nonspecifically bind to basement membranes and modify their properties, they also induce specific cellular responses including the release of profibrogenic and proinflammatory cytokines by interacting with the receptor for AGE ( RAGE). However, additional receptors could bind AGEs, adding to the complexity of this system. The kidney is both: culprit and target of AGEs. A decrease in renal function increases circulating AGE concentrations by reduced clearance as well as increased formation. On the other hand, AGEs are involved in the structural changes of progressive nephropathies such as glomerulosclerosis, interstitial fibrosis, and tubular atrophy. These effects are most prominent in diabetic nephropathy, but they also contribute to renal pathophysiology in other nondiabetic renal diseases. Interference with AGE formation has therapeutic potential for preventing the progression of chronic renal diseases, as shown from data of animal experiments and, more recently, the first clinical trials.
引用
收藏
页码:F645 / F659
页数:15
相关论文
共 173 条
  • [71] Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells
    Lu, CY
    He, JC
    Cai, WJ
    Liu, HX
    Zhu, L
    Vlassara, H
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (32) : 11767 - 11772
  • [72] ADVANCED GLYCOSYLATION END-PRODUCTS IN PATIENTS WITH DIABETIC NEPHROPATHY
    MAKITA, Z
    RADOFF, S
    RAYFIELD, EJ
    YANG, Z
    SKOLNIK, E
    DELANEY, V
    FRIEDMAN, EA
    CERAMI, A
    VLASSARA, H
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (12) : 836 - 842
  • [73] cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein
    Malherbe, P
    Richards, JG
    Gaillard, H
    Thompson, A
    Diener, C
    Schuler, A
    Huber, G
    [J]. MOLECULAR BRAIN RESEARCH, 1999, 71 (02): : 159 - 170
  • [74] Thiazolidinediones reduces endothelial expression of receptors for advanced glycation end products
    Marx, N
    Walcher, D
    Ivanova, N
    Rautzenberg, K
    Jung, A
    Friedl, R
    Hombach, V
    de Caterina, R
    Basta, G
    Wautier, MP
    Wautiers, JL
    [J]. DIABETES, 2004, 53 (10) : 2662 - 2668
  • [75] MCVERRY BA, 1980, LANCET, V1, P738
  • [76] Mené P, 1999, J AM SOC NEPHROL, V10, P1478
  • [77] Mene Paolo, 2003, Am J Cardiovasc Drugs, V3, P315
  • [78] Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo -: Evidence on the role of lipids in chemical modification of protein and development of diabetic complications
    Metz, TO
    Alderson, NL
    Chachich, ME
    Thorpe, SR
    Baynes, JW
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (43) : 42012 - 42019
  • [79] Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications
    Metz, TO
    Alderson, NL
    Thorpe, SR
    Baynes, JW
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2003, 419 (01) : 41 - 49
  • [80] Miyata T, 2000, J AM SOC NEPHROL, V11, P1719, DOI 10.1681/ASN.V1191719